Open AccessDegarelix: a new hormonal treatment for prostate cancer
Author(s) -
Mason Malcolm
Publication year - 2009
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.42
Subject(s) - prostate cancer , medicine , hormonal therapy , nice , cancer , hormone , prostate , gynecology , oncology , programming language , computer science
According to NICE, prostate cancer constitutes about 25% of new diagnoses of malignant cancer in men in England and Wales. 1 The largest single area of spending on cancer drugs is on hormonal therapy, accounting for about 40% of the £292 million total. This article focuses on a novel hormonal treatment for prostate cancer, degarelix. Copyright © 2009 John Wiley & Sons, Ltd.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom